NewLink Absorbs Big Blow As Roche Exits IDO Inhibitor Partnership
Genentech's statements about IDO as an immuno-oncology target raise questions about the future of the drug class, but IDO leader Incyte has emerged unscathed for now.
Genentech's statements about IDO as an immuno-oncology target raise questions about the future of the drug class, but IDO leader Incyte has emerged unscathed for now.